How can I reliably assess adrenal reserve in a patient taking 48 mg daily methylprednisolone?

Assessing Adrenal Reserve on Methylprednisolone 48mg Daily

You cannot reliably test adrenal reserve while taking 48mg methylprednisolone daily—you must first taper to a physiologic replacement dose (equivalent to prednisone 4-6mg daily or hydrocortisone 15-25mg daily) before testing. 1

Why Testing at 48mg is Not Recommended

At 48mg daily, methylprednisolone provides approximately 60mg prednisone-equivalent (methylprednisolone has 1.25x the potency of prednisone). This supraphysiologic dose will completely suppress your HPA axis, making any cortisol measurement meaningless—you're essentially guaranteed to have suppressed endogenous cortisol production at this dose. The 2024 European Society of Endocrinology/Endocrine Society joint guidelines explicitly recommend against routine testing for adrenal insufficiency in patients on supraphysiologic doses of glucocorticoids. 1

The Correct Approach: Taper First, Then Test

Step 1: Taper to Physiologic Dose Range

• Rapidly taper from 48mg methylprednisolone down to approximately 5-6mg methylprednisolone daily (equivalent to prednisone 4-6mg or hydrocortisone 15-25mg)
• This rapid taper is appropriate in the supraphysiologic range, assuming the underlying disease is controlled 1
• Once at physiologic doses, taper more slowly to allow HPA axis recovery

Step 2: Perform Morning Cortisol Testing

After reaching physiologic doses, measure morning serum cortisol (8:00-9:00 AM) at least 24 hours after the last methylprednisolone dose. 1

Interpretation of morning cortisol (view as a continuum, not rigid cutoffs): 1

• >300 nmol/L (10 μg/dL): HPA axis recovered—glucocorticoids can be safely stopped
• 150-300 nmol/L (5-10 μg/dL): Continue physiologic replacement, retest in weeks to months
• <150 nmol/L (5 μg/dL): Persistent adrenal insufficiency—continue physiologic replacement, retest in several months

Important Caveats

Dynamic testing (ACTH stimulation test) is NOT routinely recommended during glucocorticoid taper. 1 The guidelines explicitly suggest against it because:

• Morning cortisol is simpler, cheaper, and adequately identifies risk
• Dynamic testing rarely changes management
• Test results correlate poorly with clinically meaningful outcomes

The 24-hour washout period is critical but applies to shorter-acting glucocorticoids. For methylprednisolone (intermediate-acting with 12-36 hour duration), holding for 24 hours is appropriate. 1 However, if you were on dexamethasone (long-acting), you would need to switch to a shorter-acting agent first. 1

Alternative Approach: Clinical Monitoring Without Testing

If biochemical confirmation isn't feasible or desired, you can:

1. Continue tapering gradually while on physiologic doses
2. Closely monitor for clinical signs of adrenal insufficiency: fatigue, weakness, nausea, hypotension, hypoglycemia
3. If symptoms develop, increase dose temporarily and slow the taper 1

This approach is explicitly endorsed by the guidelines as equally valid. 1

Critical Safety Point

While tapering or after discontinuation, provide stress-dose coverage for any significant physiologic stress (surgery, severe illness, trauma) until HPA axis recovery is confirmed, as the risk of adrenal crisis exists even with biochemical testing showing recovery. 1 Patients near the 300 nmol/L cutoff may still have suboptimal stress responses. 1

If no HPA axis recovery occurs within one year on physiologic doses, refer to an endocrinology specialist. 1